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Abstract
Thrombospondin-1 (TSP-1) is a matricellular protein with regulatory functions in inflammation and cancer. The type 1
repeats (TSR) domains of TSP-1 have been shown to interact with a wide range of proteins that result in the anti-angiogenic
and anti-tumor properties of TSP-1. To ascertain possible functions and evaluate potential therapeutic effects of TSRs in
inflammatory bowel disease, we conducted clinical, histological and microarray analyses on a mouse model of induced
colitis. We used dextran sulfate sodium (DSS) to induce colitis in wild-type (WT) mice for 7 days. Simultaneously, mice were
injected with either saline or one form of TSP-1 derived recombinant proteins, containing either (1) the three type 1 repeats
of the TSP-1 (3TSR), (2) the second type 1 repeat (TSR2), or (3) TSR2 with the RFK sequence (TSR2+RFK). Total RNA isolated
from the mice colons were processed and hybridized to mouse arrays. Array data were validated by real-time qPCR and
immunohistochemistry. Histological and disease indices reveal that the mice treated with the TSRs show different patterns
of leukocytic infiltration and that 3TSR treatment was the most effective in decreasing inflammation in DSS-induced colitis.
Transcriptional profiling revealed differentially expressed (DE) genes, with the 3TSR-treated mice showing the least
deviation from the WT-water controls. In conclusion, this study shows that 3TSR treatment is effective in attenuating the
inflammatory response to DSS injury. In addition, the transcriptomics work unveils novel genetic data that suggest
beneficial application of the TSR domains in inflammatory bowel disease.
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Introduction
Thrombospondins (TSPs) are glycoproteins that are secreted
into the extracellular matrix. They have important functions in
development, inflammation, angiogenesis and cancer. The five
members of this family (TSP-1 through 5) are all multimodular
extracellular proteins. TSP-1 comprises a 450 kDA protein
composed of three 150 kDA disulfide-linked polypeptide chains
[1,2]. TSP-1 and TSP-2 organize into trimeric structures. Each
subunit of the trimer consists of multiple domains: an N-terminal
globular domain, a procollagen domain, three types of repeated
sequence motifs (type 1, type 2, and type 3 repeats) and a C-
terminal globular domain. TSP-1 and TSP-2 both have the
thrombospondin type 1 repeat, also called thrombospondin
structural repeats (TSRs). TSP-3, TSP-4 and TSP-5, on the other
hand, lack the TSRs and procollagen domain; they also differ from
TSP-1 and TSP-2 in their pentameric structure. The thrombos-
pondins have been characterized in a variety of organisms,
including Drosophila, other arthropods and vertebrates [3].
The TSRs are about 60 amino acids in length and are
evolutionarily conserved (e.g., [2], [3–5]). TSRs have roles in cell
attachment and have been implicated in binding a variety of
transmembrane and extracellular proteins. They have been shown
also to have functions in the regulation of cell proliferation, migration
and apoptosis in a variety of physiological and pathological events,
such as wound healing, inflammation and inhibition of angiogenesis
[6]. For example, by interacting with CD36 [7,8] and integrins [9],
TSRs inhibit endothelial cell migration.
The various functions of the TSRs have been attributed to
several recognition motifs. Characterization of these motifs has led
to the use of recombinant proteins that contain these motifs; these
recombinant proteins are deemed useful in cancer therapy [10,11].
The TSP-1 3TSR (that is, all three TSRs of the type 1 repeat
domain) can activate transforming growth factor beta 1 (TGFb1)
and inhibit endothelial cell migration, angiogenesis, and tumor
growth [10,12]. In an efficacy study of 3TSR on human
pancreatic cancer cells, 3TSR reduced tumor volume by 69%
and induced extensive necrosis after 3 weeks of treatment. 3TSR
treatment also reduced tumor microvessel density and increased
apoptosis in the endothelia of tumors [12].
The TGFb1 activating sequence RFK is located between the
first and second TSR. When a squamous cell carcinoma cell line
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TSR2+RFK inhibited in vivo tumor angiogenesis and growth in
the mice. The tumors were shown to have increased levels of active
TGFb1. Treatment with TSR2 without RFK produced tumors
that were slightly larger than the 3TSR and TSR2+RFK tumors
[13]. However, mimetic peptides derived from TSR2, such as
ABT-510 [14], decreased microvessel density and increased
apoptosis in gliomas. ABT-510 was also effective in diminishing
inflammation and angiogenesis in a murine model of inflamma-
tory bowel disease (IBD) [15].
In this study, we evaluated the therapeutic effects of the
subdomains of the TSP-1 TSRs using the DSS model of colitis and
used a microarray approach to analyze the transcript profile of the
mice treated with DSS and the TSRs. Our goals were to gain
insight into the genes and pathways that are regulated upon TSR
treatment and to determine the specific TSR treatment that would
have the best potential for drug therapy. We were also interested
in identifying novel genes not yet associated with and character-
ized in IBD, as well as putative intestinal stem cell genes. The
results herein establish the efficacy of the 3TSR-containing
recombinant protein in alleviating the inflammatory response to
DSS injury as shown by improved clinical signs and lower
perturbation of the transcriptome.
Materials and Methods
Mice
Wild-type (WT) mice (strain C57BL/6; n=48) were purchased
from Charles River Laboratories International (Wilmington, MA).
Mice were bred at room temperature at the Wilkes University
vivarium. All animal procedures were performed with the
approval of the Wilkes University Institutional Animal Care and
Use Committee and the U.S. National Institutes of Health (NIH)
guidelines (Wilkes IACUC protocol # 189).
Dextran sulfate sodium (DSS) and TSR Treatments
DSS (MW: 36,000,50,000) (MP Biomedical, LLC, Aurora,
OH) was dissolved in the drinking water (distilled) of the mice at a
dilution of 2.5% (wt/vol) and administered to 6–7 week old mice
for 7 days to induce acute colitis. Simultaneously, mice were
subcutaneously injected daily with the following recombinant
proteins: 3TSR (n=10), TSR2 (n=9) TSR2+RFK (n=15). TSR
doses were administered according to published results [10]. As a
control for the TSR treatment, mice (n=14) were injected with
saline. Following 7 days of DSS administration, mice were
sacrificed by CO2 asphyxiation.
Recombinant proteins were obtained from Dr. Jack Lawler
(Harvard Medical School, Boston, MA). The 3TSR contains
amino acids 361–530 of TSP-1; TSR2, amino acids 416–473;
TSR2+RFK, amino acids 411–473 [10].
Clinical parameters and Disease Activity Indices
The clinical severity of the colitis was determined daily by
disease activity indices according to a published protocol [15].
Stool consistency was evaluated as follows: formed feces=1, soft
consistency=2 and liquid feces=3. Presence of fecal occult blood
was tested using the stool guaiac test; scoring was done as follows:
1 for negative by guaiac paper, 2 for positive only with guaiac
paper, 3 for bloody feces.
Histology and inflammation grading in colonic tissues
Intestines were removed, opened longitudinally, and rinsed with
ice-cold PBS. For morphologic studies, tissues were fixed in
Histochoice MB fixative (Electron Microscopic Sciences, Hatfield,
PA) overnight, processed and cut in serial 5-mm sections. Sections
were stained with hematoxylin and eosin (H&E) for histopatho-
logical analysis. Inflammation was graded as follows: 0, no
inflammation; 1, modest numbers of infiltrating leukocytes in the
lamina propria; 2, infiltration of leukocytes leading to separation of
crypts and mild mucosal hyperplasia; 3, massive infiltration of
inflammatory cells accompanied by disrupted mucosal architec-
ture and complete loss of goblet cells. Slides were double-coded
before pictures were taken and frames blindly analyzed in a
monitor.
RNA isolation
Colon segments (,1 cm long) were collected from treated and
untreated mice and snap-frozen in liquid nitrogen. Total RNA was
extracted from these tissues using the RNAqueousH-4PCR kit
(Applied Biosystems), following the manufacturer’s instructions.
RNA was DNase I-treated and quantified using the Nanodrop
ND1000 spectrometer (Thermo Scientific, Wilmington, DE).
RNA integrity was checked on a non-denaturing agarose gel.
The microarray experiments are described in the following
sections following the MIAME guidelines.
Microarray Processing
Total RNA from colons of at least three mice from each
treatment group were submitted to the Center for Functional
Genomics, University at Albany, Rensselaer, New York, for
microarray processing. Treatment groups included the mice
treated with DSS and the TSR-containing recombinant proteins
3TSR, TSR2 and TSR2+RFK and mice treated with DSS+ saline
injections as controls. Untreated WT were used as additional
control. RNA integrity of the samples used for microarray
hybridization was verified using Agilent’s 2100 Bioanalyzer (Santa
Clara, CA). The Affymetrix (Santa Clara, CA) Mouse Gene 1.0
ST Array was used for the transcript profiling. 20 ng total RNA
per sample was processed using WT Ovation Pico RNA
Amplification System (NuGEN Technologies, Inc., San Carlos,
CA). Sense target cDNAs were generated using the standard
NuGEN WT protocol and hybridized to the arrays. Arrays were
washed, stained on a FS 450 station and scanned on a GeneChip
3000 7G scanner using GeneChipH Command ConsoleH Software
(AGCC).
Statistical Analysis
Statistical analysis of the CEL files was done using GeneSpring
GX 11.5.1 (Agilent Technologies). Signals were quantile-normal-
ized using PLIER16 algorithm and baseline-transformed to the
median of all samples. The log2 normalized signal values were
filtered to remove entities that show signal in the bottom 20th
percentile across all samples. This list was further filtered to only
include entities where at least 1 out of 6 conditions have
CV,20.0% (that is, to remove probes that are highly variable
across replicates in a condition). The list was then subjected to
ANOVA (p,0.05) that compares all conditions to the WT-water
or WT-DSS saline condition. A Benjamini-Hochberg False
Discovery Rate correction (p,0.05) was also included in the
analysis. A 1.5-fold filter was applied to identify genes that are
differentially expressed between any two specific conditions.
Microarray data have been deposited in the Gene Expression
Omnibus (GEO) database under accession number GSE32697.
Real-Time Quantitative PCR Validation of Array Data
Real-time quantitative PCR (RT-qPCR) was performed on
colonic total RNA isolated from another set of three mice. To
TSR in Inflammatory Bowel Disease
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High Capacity RNA-to-cDNA Kit (Applied Biosystems). This was
followed by amplification of the undiluted cDNAs with the Fast
SYBR Green master mix (Applied Biosystems) and real-time
quantification in the StepOne Plus Real-time PCR system.
Amplification was performed with 40 cycles of 95uC for 3 sec,
and 60uC for 30 sec, using 150 nM of each primer.
The use of Gapdh as endogenous control gene in the RT-qPCR
validation was problematic with samples that were treated with the
recombinant proteins. Preliminary qPCR runs showed fluctuating
levels of Gapdh among the TSR-treated samples. Ubc, Gapdh, Rps23
and Tpt1 have been evaluated for suitability as internal control in
colon cancer studies [16]. Using the GeneMANIA [17] prediction
server (www.genemania.org), we found that Gapdh interacts with
Igfbp5 (Figure S2). Our array data shows that Igfbp5 is up-regulated
in WT-DSS mice. The Gapdh-Igfbp5 interaction suggests co-
expression and could explain the high variability of Gapdh
expression in our samples. On the other hand, query of Tpt1 in
GeneMANIA showed that it is unrelated to any of our genes of
interest.
For the RT-qPCR validation, we selected (1) representative
genes from the major pathways that are activated as a response to
inflammation, (2) genes that code for acute phase proteins, and (3)
genes that have not been extensively characterized, especially in
IBD. The genes validated are: calcyphosine-like (Capsl), carbonyl
reductase 3 (Cbr3), CXC chemokine ligand 5 (Cxcl5), epiregulin
(Ereg), haptoglobin (Hp), inhibin A (InhbA), pentraxin related gene
(Ptx3), insulin-like growth factor binding protein 5 (Igfbp5), matrix
metallopeptidase 10 (Mmp10, also known as stromelysin-2),
Mmp13, WAP four-disulfide core domain 12 (Wfdc12), serglycin
(Srgn), Serine (or cysteine) peptidase inhibitor, clade A, member 3N
(Serpina3N), formyl peptide receptor (Fpr3) and leucine-rich repeat-
containing G-protein coupled receptor (Lgr5). Expression levels of
the 15 genes were normalized to the internal control, Tpt1 (tumor
protein, translationally-controlled 1). The 2‘-ddCt method was
used to quantify the expression levels of the genes. Details on the
reference and target genes are given in the Table S1.
Immunohistochemistry (IHC)
IHC sections were incubated overnight with the following
antibodies: cluster of differentiation 31 (CD31) and Ly-6G/Ly-6C
(RB6-8C5) (BD Pharmingen, San Diego, CA), mouse panen-
dothelial cell antigen (MECA-32) (BioLegend, San Diego, CA),
Interleukin-6 (IL-6), cluster of differentiation 68 (Mac/CD68) and
metalloproteinase 3 (MMP3) (Santa Cruz Biotechnologies Inc.
Santa Cruz, CA), LGR5 and Calgranulin MRP8/S100A9
(Epitomics, Burlingame, CA). Sections were further incubated
with biotinylated anti-rabbit, anti-goat or anti-rat IgG IMPRESS
(Vector Laboratories, Burlingame, CA) respectively for 30 min-
utes. Finally, color was developed using a 3,39-diaminobenzidine
substrate kit (BD Pharmingen).
Evaluation of microvascular density (MVD)
MVD was determined in colon sections of the treated mice.
Sections stained with CD31/MECA antibodies were screened for
colitic lesions. Serial pictures were taken at high power (6400)
using a digital camera (Olympus Corporation, Tokyo, Japan),
covering both mucosa and submucosa. Images were blindly
evaluated; MVD was assessed by counting the vessels in lesions in
which endothelial cells were positive for MECA/CD31.
Evaluation of leukocytic infiltration
Slides stained with antibodies CD68 for macrophages and Ly-
6G/Ly-6C for granulocytes were scanned at low magnification
and examined for areas with the highest number of leukocytic
infiltration. The number of positive cells stained with Mac/CD68
or Ly-6G/Ly-6C was assessed at 4006magnification per field.
Results
Only 3TSR ameliorated clinical signs of colitis in the DSS-
induced colitis
The presence of fecal blood was evaluated and rated in mice
with DSS-induced colitis and treated with the TSRs (Figure 1A).
While no significant differences were observed during the first 5
days of treatment, by days 6 and 7, 3TSR mice showed lesser fecal
bleeding when compared with mice treated with saline, TSR2 and
TSR2+RFK (day 6, 3TSR and saline p=0.020; day 7, 3TSR and
saline p=0.045). Fecal consistency was also evaluated daily
(Figure 1B). Again, by day 7, 3TSR mice displayed more solid
feces compared to the liquid feces of saline-treated mice
(p,0.0001) and TSR2+RFK (p,0.0001). TSR2 and TSR2+RFK
mice showed more severe diarrhea than the controls (p,0.0001).
Inflammation and epithelial injury were significantly decreased in
colons of the 3TSR mice when compared with the saline-treated
mice (p=0.001) (Figure 1C). Differences between 3TSR and the
other two recombinant proteins were statistically significant (3TSR
and TSR2+RFK: p=0.034; 3TSR and TSR2: p=0.025)
(Figure 1D).
Angiogenesis was not inhibited by the TSRs
By using CD31/Meca stained slides, endothelial cells lining
blood vessels were analyzed in colonic sections (Figure S1) from
the treated mice. Vessel counts were not statistically different
across the treatments (p=0.074; 3TSR, n=29, ves-
sels=21.4862.1 and TSR2+RFK, n=35, vessels=21.461.5).
However, colonic sections from TSR2 mice showed a trend for
lower counts (n=20, vessels=19.4562.7) when compared to
saline-treated colons (n=16, vessels=26.6264.0) (Figure S1).
Colonic tissues from TSR-treated mice showed
differential patterns of leukocytic infiltration
Sections stained with the antibody Ly-6G/Ly-6C were evaluated
to identify granulocytes and monocytes (Figure 2A). Colonic
sections from 3TSR- and TSR2-treated mice showed counts
considerably lower than saline-treated colons, (with p=0.030 and
0.047, respectively) (Figure 2B). Interestingly, counts obtained from
the TSR2+RFK-treated colons were similar to the ones detected in
saline-treated colons. The differences between TSR2 and
TSR2+RFK were statistically significant (p=0.021).
Macrophage infiltration was analyzed using Mac/CD68
antibody staining (Figure 2C). Though no differences were
detected when each group was compared with the saline control,
TSR2+RFK mice showed a significantly lower influx of
macrophages compared with the controls and the TSR2 and
3TSR groups (p=0.0006) (Figure 2D).
TSR treatment reduced the number of differentially
expressed genes in the DSS induced colitis
Coincident treatment with 3TSR, TSR2+RFK and TSR2 show
diminishing numbers of DE genes, with 3TSR showing the least
number of DE genes (Figure 3A) when compared to either controls,
WT-water or WT-DSS saline. The general trend of number of DE
genes (when compared to WT-water) is as follows: WT-DSS-
TSR2.WT-DSS-TSR2+RFK.WT-DSS-3TSR.WT-DSS-saline
(Figure 3A). A heatmap of the top DE genes, eight up-regulated and
four down-regulated, is shown in Figure 3B and the gene list is
TSR in Inflammatory Bowel Disease
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regulated and two genes were down-regulated in the 3TSR vs WT-
DSS saline comparison. Figure 3C presents a heatmap of the top 14
DEgenesinthispair.Thenumbersofup-anddown-regulatedgenes
in the 3TSR treatment group diminished when compared to either
TSR2 or TSR+RFK (Figures 3D and 3E). Table 2 presents the top
12 genes that are up-regulated in the 3TSR-treated group and the
two down-regulated genes, using the WT-DSS-saline as reference.
Although some genes involved in the inflammatory response were
up-regulated in 3TSR, their level of up-regulation was much lower
than in the other TSR treatment groups. The complete list of
differentially expressed genes (FC.1.5; p,0.1) is provided in the
Table S2.
DSS and the TSR treatments up-regulated key genes
involved in inflammation, cell adhesion and apoptosis
Genes up-regulated in the DSS and TSR-treatment groups
belong to the following pathways: (1) matrix metalloproteinases, (2)
inflammatory response, (3) peptide GPCRs, (4) eicosanoid/
prostaglandin synthesis regulation, (5) TGF-beta signaling, (6)
Figure 1. Fecal blood and consistency rating in mice treated with DSS and TSRs over one week. While no significant differences were
observedduringthefirst days of treatment, bydays 6 and7,mice treated with the 3TSR (n=10) showedlesser fecalbleedingwhen comparedwith mice
treated with the saline (n=14), TSR2 (n=9) and TSR2+RFK (n=15), (day 6: p=0.02; day 7: p=0.045, asterisk) (A). Fecal consistency was also evaluated
daily (B). By day 7, 3TSR mice displayed more solid feces compared to the liquid feces of saline-treated mice (p,0.0001, asterisk) and TSR2+RFK
(p,0.0001). Inflammation grading (C, D) was assessed andH&Estainedsections. Decreased inflammation was observed in sections of colons from 3TSR-
treated mice (n=9) compared to colons from mice treated with TSR2+RFK (n=12), TSR2 (n=10) and saline (n=7). 4006original magnification.
doi:10.1371/journal.pone.0034590.g001
Figure 2. Immunohistochemistry (IHC) with the Ly-6G/Ly-6C antibody for detection of granulocytes and monocytes in colitic
sections. Counts of Ly-6G/Ly-6C positive cells in TSR2 and 3TSR were considerably lower than in saline (n=5 in each group) and TSR2+RFK-treated
(n=9) colons (A). However, only TSR2 showed lower counts that were statistically significant, p=0.047 (B). IHC against Mac/CD68 (C) showed fewer
CD68 positive cells (macrophages) in TSR2+RFK (n=24) compared to TSR2 (n=14) and saline (n=18). These differences were statistically significant,
p=0.0006, when compared with 3TSR-treated (n=18) colons (D). 4006magnification.
doi:10.1371/journal.pone.0034590.g002
TSR in Inflammatory Bowel Disease
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and (8) apoptosis (Table 3). S100 calcium binding protein A9
(S100a9; also known as calgranulin B) had the highest transcript
level in all treatment groups, with the WT-DSS group showing the
highest FC (81), whereas the WT-DSS-3TSR has FC=18 (Table
S2). An inflammatory response was indicated by the high
transcript levels of Il-6 [WT-DSS-TSR2 (FC=18).WT-DSS-
TSR2+RFK (FC=7).WT-DSS-3TSR (FC=4)]. Chemokines,
specifically Cxcl2, Cxcl5, Cxcl13, Cxcl16, Ccl3 and Ccl7, were also
up-regulated (FC=2 to 60) in the treated samples. Cxcl2,i n
particular, had the greatest increase in the WT-DSS-TSR2
(FC=55) compared to the other TSR-treated mice. Genes
involved in inflammation and angiogenesis including Adamts9,
Tnf alpha and the TNF receptor Tnfrsf1b, were enriched the most
in the WT-DSS and WT-DSS-TSR2 groups.
Genes coding for proteins that are well known to interact with
TSP-1 during inflammation were differentially expressed in DSS
and TSR-treated mice, except in the 3TSR group. Cd47 was only
slightly up-regulated in WT-DSS-TSR2 (1.8). It was not DE in
TSR2+RFK and 3TSR. Tgfb1 was also slightly up-regulated in
TSR2 (FC=2.5) and TSR2+RFK (FC=1.8), but not in 3TSR.
None of the treatment samples showed differential expression of
Cd36.
Real-time qPCR validation
Actual qPCR data revealed no fluctuation in expression of the
internal control gene, Tpt1, which was consistent with the
microarray data. We validated 15 DE genes to verify the array
data. Figure 4 summarizes the validation for representative genes
coding for acute phase proteins, growth factors and novel proteins.
Validation for the metalloproteinases and genes coding for
cytokines and a protein important for intestinal homeostasis are
shown in Figure S3. Although Srgn and Wfdc12 have p-values
greater than 0.05, (Srgn p=0.056, Wfdc12 p=0.065), the real-time
qPCR validation shows that they are indeed differentially
expressed.
Figure 3. Differentially expressed genes in paired sets of comparison between the treatment and the control groups. Comparison of
treatment groups with WT-water (A, upper panel of table) and WT-DSS saline controls (A, lower panel). Total DE genes refer to all genes that are up-
or down-regulated by .1.5-fold at 95% confidence level. The 3TSR-treatment group clearly shows the least transcriptional perturbation among the
TSR treatment groups. (B) A heatmap of the top 12 DE genes in the comparison that uses WT-water as the control. Capsl, Cbr3, Abhd3 and
0610011F06Rik are down-regulated in the TSR treatment groups. (C) A heatmap of the top DE genes in the 3TSR-treated group. The number of up-
and down-regulated genes in the TSR treatment groups (when compared to the WT-water control) are presented in (D); (E) shows the breakdown of
the DE genes in comparison to the WT-DSS saline.
doi:10.1371/journal.pone.0034590.g003
TSR in Inflammatory Bowel Disease
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cancer and inflammation
Array data show that Lgr5, an intestinal stem cell biomarker
[18,19], was down-regulated in the TSR2-treated WT mice. Lgr5
was not differentially expressed in the 3TSR and TSR2+RFK
mice. However, results obtained in the RT-qPCR validation show
that Lgr5 was significantly down-regulated in the TSR2+RFK
(Figure 4B).
MMP3, IL-6 and Calgranulin (MRP8) are relevant in
angiogenesis and inflammation. Validation by IHC of these genes
(Figure 5) showed the MMP3 protein localized in the cytoplasm of
epithelial cells and endothelial cells. Strong positive staining for
MMP3 was detected mainly in monocytes, polymorphonuclears,
plasma and fibroblasts. Stromal staining was detected in the
submucosa. Endothelial cells and the leukocytic infiltrate in
inflamed areas were positive for IL-6. MRP8 staining was
observed almost exclusively in polymorphonuclears.
Discussion
Our results indicate that 3TSR suppressed the inflammatory
response induced by DSS injury and these data are supported by
the array results. For pharmacological consideration, it is logical to
assume that the lesser the perturbation of the transcriptome, the
better the clinical outcome. Our results also confirm the finding
that TSR2 is less effective than either 3TSR or TSR2+RFK [10].
3TSR has been shown to induce endothelial cell apoptosis and
inhibit tumor growth [11]. This function may be correlated to the
modulation of VEGFR2 function by TSP-1 and 3TSR [20].
One of the unexpected findings when clinical parameters were
evaluated was the severity of the bleeding and diarrhea in mice
treated with TSR2 and TSR2+RFK. These results do not agree
with previous studies using the ABT-510, a TSR2 mimetic peptide
[15]. In the ABT-510 studies, osmotic mini-pumps were used for
the continuous delivery of the peptide in contrast to the daily
injections used in this study. Moreover, increased eNOS activity
has been attributed to increased mucosal blood flow in induced
colitis [21] and TSP-1 is known to regulate nitric oxide (NO)
signaling [22]. Noteworthy is the lesser influx of granulocytes in
the TSR2 mice compared to the TSR2+RFK and the 3TSR. This
suggests that the TSR2 domain inhibits the influx of granulocytes
independently of the RFK domain. TSR2 has been demonstrated
to inhibit the secretion of NO during the acute phase of
inflammation, and therefore decreasing the trafficking of neutro-
phils [23]. On the other hand, RFK presumably inhibits
inflammation by activating TGFß1. However, recent studies
suggest that when there is a high secretion of IL-1 and IL-6,
TGFb1 will favor the production of Th17 cells. Th17 cells secrete
pro-inflammatory cytokines and metalloproteinases that exacer-
bate the inflammatory response [23].
Our array data showed that metalloproteases and chemokines
such as MMP10, MMP13, the CCs and CXCs are involved in the
pathogenesis of DSS colitis. Expression of Cxcl2 and Cxcl5 (Figure
S3B), the proteins of which are known to target neutrophils and
have suspected roles in IBD, was significantly increased in the DSS
and TSR-treated mice during the acute phase of colitis. The
increase in Cxcl2 expression is the same observation reported for
the leptin receptor-deficient mice that were treated with DSS [24].
An irregularity in chemokine signaling could jeopardize epithelial
integrity, which could lead to the breakdown of defense against
invading pathogens. Moreover, Cxcl5 has a great potential in
eliciting a pro-angiogenic phenotype [25].
The concentration of acute phase proteins is known to increase
or decrease during inflammation. Hp and Ptx3, both of which are
enriched in the DSS and TSR-treated mice, code for acute phase
proteins. In a study of Hungarian patients with Crohn’s disease
(CD), Hp polymorphism was determined to be associated with CD
and inflammatory disease behavior [26]. Hp has been suggested to
have a protective role in inflammatory colitis [27]. Ptx3 has been
annotated to ‘‘positive regulation of nitric oxide biosynthetic
process’’ and to ‘‘zymosan binding’’.
This study showed strong evidence for the alteration of gene
expression in DSS-induced colitis that supports vulnerability to
cancer. As an example, calgranulins, S100A8/A9 (calgranulins A
and B, respectively), have been detected in various human cancers;
hence they have been suggested to play a key role in inflammation-
associated cancer [28]. They support epithelial barrier function and
mediate responses to infection and inflammation [29] by amplifying
pro-inflammatory responses [30]. In gastrointestinal epithelial cells,
their expression is induced during inflammation and increased
protein expression of S100A9 has been detected in colitis-related
carcinogenesis in mice [31]. Key genes associated with colon tumor
progression are reportedly activated by S100A8/A9 [32].
The ‘novel’ genes that we validated appear to have a role, one
way or another, in inflammatory response and the promotion of
inflammation-related cancer development. The function of these
Table 3. Major pathways activated and genes enriched in the DSS- and TSR-treated mice.
Pathways Genes up-regulated (fold change.2.0, p,0.05)
Matrix metalloproteinases Matrix metallopeptidases 2, 3, 8, 10, 12, 13, 14
Inflammatory response Interleukin 1 alpha (IL1a), IL1a ˆ, IL-6, Interleukin 4 receptor, alpha (Il4ra), Il1r2
Peptide GPCRs Formyl peptide receptor 3 (Fpr3|2)
Eicosanoid/prostaglandin synthesis regulation Prostaglandin-endoperoxide synthase 2 (Ptgs2)
TGF-beta signaling Inhibin beta-A (Inhba)
Smooth muscle contraction Insulin-like growth factor binding protein 5 (Igfbp5)
Blood clotting cascade/Wnt signaling Plasminogen activator, urokinase (Plau)
Integrin-mediated cell adhesion Integrins alpha M (Itgam), beta 2 (Itgb2), Itga4
Apoptosis B-cell leukemia/lymphoma 2 related protein A1a (Bcl2a1a), Bcl2a1b, Bcl2a1c, Bcl2a1d; Tumor
necrosis factor (Tnf), TNF receptor superfamily, member 1a (Tnfrsf1a), Tnfrsf1b
Ovarian Infertility Genes Early growth response 2 (Egr2),
CCAAT/enhancer binding protein (C/EBP), beta (Cebpb)
doi:10.1371/journal.pone.0034590.t003
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other genes have not been extensively studied. The description
ascribed to them in the gene ontology database, however, indicates
some involvement in the development of physiological disorders.
Genome-wide association studies have identified Capsl to have
association with type 1 diabetes [33] and the autoimmune thyroid
disease Graves’ disease [34]. Cbr3, an enzyme that reduces
carbonyl groups in xenobiotics and endogenous compounds such
Figure 4. SyBR Green-based RT-qPCR validation of array data. Signal intensities were normalized to the endogenous control, Tpt1. Fold
changes are the averages of three biological replicates different from those used in the microarrays. Linear FC values were log2-transformed. Hp and
Ptx3 code for acute phase proteins (A). We classified Capsl, Cbr3, Ereg, Fpr3, Serpina3n and Lgr5 as novel genes (B) because they have not been
characterized in IBD. Growth factors are clearly up-regulated (C).
doi:10.1371/journal.pone.0034590.g004
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role in xenobiotic metabolism in humans [35]. Ereg is a growth
factor that resides in the extracellular space and is a marker for
ovarian cancer development [36]. Fpr3 is a member of a G-protein
coupled receptor family that controls immune responses such as
leukocyte chemotaxis and activation [37]. Serpina3n has been found
to inhibit human Granzyme B activity in sertoli cells as a
mechanism to suppress the immune response [38].
SRGN is a proteoglycan that has important roles in inflamma-
tory reactions [39]. In human endothelial cells, it co-localizes and
interacts with tissue-type plasminogen activator (PLAT) [40]. In
macrophages, where it is the major secreted proteoglycan, it
regulates the secretion of TNF [41]. The up-regulation of Srgn
(Figure S3B) in the DSS- and TSR-treated mice suggests that it is a
component of the immune response in these mice.
The significance of Wfdc12 up-regulation in the DSS- and TSR-
treated mice (Figure S3C), lies in the fact that an altered
microbiota composition in the intestinal tract characterizes the
pathogenesis of IBD [42,43]. WFDC12 is an antibacterial protein
that inhibits the growth of both E. coli and S. aureus at a IC90 of
10 mM [44]. With its anti-infective activity, it could serve as
mucosal defense against pathogenic bacterial strains, in conjunc-
tion with chemokine signaling.
Evidence for involvement of Insulin-like growth factor (IGF)
signaling in cancerprogression hasbeenincreasing [45].IGF signaling
plays a critical role in promoting cell survival and proliferation of
embryonic and adult stem cells [46]. IGFBP5 is associated with
‘‘stemness’’ and its expression has been linked to LGR5, which has
been shown to be expressed in cycling columnar epithelial cells at the
intestinal crypt base [18,19]. LGR5-deficient mice showed decreased
Igfbp5 expression [47]. Erosive lesions in the intestinal epithelium due
to DSS could account for the lower transcript levels of Lgr5 in the
DSS-treated mice. LGR5 deficiency was reported to deregulate the
Wnt pathway and contribute to cancer [47].
In conclusion, this study showed that the 3TSR have anti-
inflammatory properties that seem to be independent of any
angiogenic inhibition or ability to activate TGFß1. These data
highlight the anti-inflammatory functions of the 3TSR of TSP-1 in
the mouse intestine and its potential use as novel therapeutic tool
in IBD. The transcript profiles of the treatment groups showed a
pool of genes involved in critical pathways of inflammation. The
identification of these genes has implications in improving our
Figure 5. IHC of MMP3, IL-6 and MRP8. Protein expression of MMP3 was localized in colonocytes, leukocytes and endothelial cells. Staining was
particularly intense in the submucosal stroma of colitic areas. IL-6 was detected in the leukocytic infiltrate and endothelial cells. Calgranulin or MRP8
also showed selective staining in the leukocytic infiltrate.
doi:10.1371/journal.pone.0034590.g005
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ization of their protein products and their interactions could
provide leads in the development of other drug therapy for IBD.
Supporting Information
Figure S1 Assessment of microvessel counts. Using
combined MECA/CD31 antibodies (A), fewer blood vessels were
observed in sections from TSR2 mice (n=20) compared to
sections from mice treated with TSR2+RFK (n=35), 3TSR
(n=29) or saline (n=16), (B). 4006magnification.
(TIF)
Figure S2 A functional association network of selected
mouse genes. GeneMANIA, a web interface for predicting gene
function and determining usability of genes for functional assays
(www.genemania.org) was used to determine suitability of
endogenous control genes for validating array data by RT-qPCR.
The following genes (grey circles) were inputted in GeneMANIA:
Ubc; Tpt1; Rps23; Gapdh; Capsl; Igfbp5; Fpr3; Srgn; Kcne3; Mmp10;
Mmp13; Wfdc12. The network generated shows interaction
between Gapdh and Igfbp5; therefore, Gapdh expression is likely to
be co-expressed with Igfbp5 and show varying expression levels
similar to that of Igfbp5. Tpt1, on the other hand, has no predicted
interaction with any of the input genes.
(TIF)
Figure S3 Additional RT-qPCR validation of array data.
(TIF)
Table S1 Genes used for the RT-qPCR validation and
their primers. Tpt1 was used as the control gene after it was
found to show no fluctuation compared to four other genes that
were tested.
(XLSX)
Table S2 ANOVA list of genes that were differentially
expressed in the colons of DSS and TSR-treated mice.
(XLS)
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